{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:49:27Z","timestamp":1774291767913,"version":"3.50.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":2411,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"NIH\/NHLBI"},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wyeth\/Pfizer"},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004702","name":"Baxter International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1111\/jth.13301","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T07:33:44Z","timestamp":1456731224000},"page":"894-905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies"],"prefix":"10.1016","volume":"14","author":[{"given":"T.C.","family":"Nichols","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Agers\u00f8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ezban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lillicrap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13301_bb0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/B978-0-12-394596-9.00006-8","article-title":"Animal models of hemophilia","volume":"105","author":"Sabatino","year":"2012","journal-title":"Prog Mol Biol Transl Sci."},{"key":"10.1111\/jth.13301_bb0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1053\/j.seminhematol.2013.03.023","article-title":"Animal models of hemophilia and related bleeding disorders","volume":"50","author":"Lozier","year":"2013","journal-title":"Semin Hematol"},{"key":"10.1111\/jth.13301_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1084\/jem.90.2.97","article-title":"Canine hemophilia; observations on the course, the clotting anomaly, and the effect of blood transfusions","volume":"90","author":"Graham","year":"1949","journal-title":"J Exp Med"},{"key":"10.1111\/jth.13301_bb0025","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1055\/s-0037-1613063","article-title":"Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia","volume":"87","author":"Hough","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13301_bb0030","doi-asserted-by":"crossref","first-page":"12991","DOI":"10.1073\/pnas.192219599","article-title":"The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion","volume":"99","author":"Lozier","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.13301_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-0038-1651541","article-title":"The development of homologous (canine\/anti\u2010canine) antibodies in dogs with haemophilia A (factor VIII deficiency): a ten\u2010year longitudinal study","volume":"69","author":"Tinlin","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13301_bb0040","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia A following liver gene therapy","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0045","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3270","article-title":"Endogenous factor VIII synthesis from the intron 22\u2010inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A","volume":"19","author":"Pandey","year":"2013","journal-title":"Nat Med"},{"key":"10.1111\/jth.13301_bb0050","doi-asserted-by":"crossref","first-page":"10095","DOI":"10.1073\/pnas.86.24.10095","article-title":"Canine hemophilia B resulting from a point mutation with unusual consequences","volume":"86","author":"Evans","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.13301_bb0055","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","article-title":"AAV liver expression of FIX\u2010Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice","volume":"125","author":"Crudele","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2004-02-0464","article-title":"Re\u2010establishment of VWF\u2010dependent Weibel\u2010Palade bodies in VWD endothelial cells","volume":"105","author":"Haberichter","year":"2005","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0065","first-page":"713","article-title":"Canine von Willebrand's disease","volume":"76","author":"Dodds","year":"1970","journal-title":"J Lab Clin Med"},{"key":"10.1111\/jth.13301_bb0070","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/s-0037-1615197","article-title":"Identification of mutations in the canine von Willebrand factor gene associated with type III von Willebrand disease","volume":"80","author":"Rieger","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13301_bb0075","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1538-7836.2006.02203.x","article-title":"A novel missense mutation responsible for factor VII deficiency in research Beagle colonies","volume":"4","author":"Callan","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13301_bb0080","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.exphem.2003.09.005","article-title":"Correction of a large animal model of type I Glanzmann's thrombasthenia by nonmyeloablative bone marrow transplantation","volume":"31","author":"Niemeyer","year":"2003","journal-title":"Exp Hematol"},{"issue":"Suppl. 3","key":"10.1111\/jth.13301_bb0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2516.2010.02255.x","article-title":"Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B","volume":"16","author":"Nichols","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13301_bb0090","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00003088-200140110-00003","article-title":"Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia","volume":"40","author":"Bjorkman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jth.13301_bb0095","first-page":"637","article-title":"Effect of antihemophilic factor on one\u2010stage clotting tests; a presumptive test for hemophilia and a simple one\u2010stage antihemophilic factor assy procedure","volume":"41","author":"Langdell","year":"1953","journal-title":"J Lab Clin Med"},{"key":"10.1111\/jth.13301_bb0100","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/ajcp\/36.3.212","article-title":"The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies","volume":"36","author":"Proctor","year":"1961","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/jth.13301_bb0105","first-page":"6","article-title":"Physiologic basis of transfusion therapy in hemophilia","volume":"61","author":"Brinkhous","year":"1956","journal-title":"AMA Arch Pathol."},{"key":"10.1111\/jth.13301_bb0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3324\/haematol.2014.112821","article-title":"Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity","volume":"100","author":"Oldenburg","year":"2015","journal-title":"Haematologica"},{"key":"10.1111\/jth.13301_bb0115","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/312326a0","article-title":"Characterization of the human factor VIII gene","volume":"312","author":"Gitschier","year":"1984","journal-title":"Nature"},{"key":"10.1111\/jth.13301_bb0120","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/312342a0","article-title":"Molecular cloning of a cDNA encoding human antihaemophilic factor","volume":"312","author":"Toole","year":"1984","journal-title":"Nature"},{"key":"10.1111\/jth.13301_bb0125","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.V72.1.335.bloodjournal721335","article-title":"In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency)","volume":"72","author":"Giles","year":"1988","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0130","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM198901193200307","article-title":"Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia","volume":"320","author":"White","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13301_bb0135","doi-asserted-by":"crossref","first-page":"e963","DOI":"10.1111\/j.1365-2516.2011.02580.x","article-title":"Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs","volume":"17","author":"Karpf","year":"2011","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13301_bb0140","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-2002-32661","article-title":"Preclinical pharmacology of albumin\u2010free B\u2010domain deleted recombinant factor VIII","volume":"28","author":"Brinkhous","year":"2002","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.13301_bb0145","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2011-08-367813","article-title":"Prolonged activity of a recombinant factor VIII\u2010Fc fusion protein in hemophilia A mice and dogs","volume":"119","author":"Dumont","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0150","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2516.2012.02896.x","article-title":"Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8\u2010GP in haemophilia A dogs","volume":"18","author":"Agerso","year":"2012","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13301_bb0155","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first\u2010in\u2010human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13301_bb0160","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full\u2010length, recombinant factor VIII for prophylactic and on\u2010demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0165","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1182\/blood.V88.11.4209.bloodjournal88114209","article-title":"The cDNA and derived amino acid sequence of porcine factor VIII","volume":"88","author":"Healey","year":"1996","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0170","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-0037-1614984","article-title":"The canine factor VIII cDNA and 5\u2019 flanking sequence","volume":"79","author":"Cameron","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13301_bb0175","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1182\/blood-2009-05-220327","article-title":"Recombinant canine B\u2010domain deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model","volume":"114","author":"Sabatino","year":"2009","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0180","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2012-10-464164","article-title":"Minimal modification in the factor VIII B\u2010domain sequence ameliorates the murine hemophilia A phenotype","volume":"121","author":"Siner","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0185","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1073\/pnas.79.21.6461","article-title":"Isolation and characterization of a cDNA coding for human factor IX","volume":"79","author":"Kurachi","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.13301_bb0190","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/299178a0","article-title":"Molecular cloning of the gene for human anti\u2010haemophilic factor IX","volume":"299","author":"Choo","year":"1982","journal-title":"Nature"},{"key":"10.1111\/jth.13301_bb0195","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1021\/bi00335a049","article-title":"Nucleotide sequence of the gene for human factor IX (antihemophilic factor B)","volume":"24","author":"Yoshitake","year":"1985","journal-title":"Biochemistry"},{"key":"10.1111\/jth.13301_bb0200","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1182\/blood.V88.7.2603.bloodjournal8872603","article-title":"Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B","volume":"88","author":"Brinkhous","year":"1996","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0205","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood.V74.1.207.207","article-title":"Molecular cloning of a cDNA encoding canine factor IX","volume":"74","author":"Evans","year":"1989","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/humc.2014.153","article-title":"Translational data from adeno\u2010associated virus\u2010mediated gene therapy of hemophilia B in dogs","volume":"26","author":"Nichols","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1111\/jth.13301_bb0215","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2012-06-440123","article-title":"The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy","volume":"120","author":"Finn","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0220","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta\u2010analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0225","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"DiMichele","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13301_bb0230","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1073\/pnas.83.8.2412","article-title":"Characterization of a cDNA coding for human factor VII","volume":"83","author":"Hagen","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl. 1","key":"10.1111\/jth.13301_bb0235","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0268-960X(15)30002-3","article-title":"Recombinant activated factor VII: 30 years of research and innovation","volume":"29","author":"Hedner","year":"2015","journal-title":"Blood Rev"},{"key":"10.1111\/jth.13301_bb0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2141.2010.08432.x","article-title":"Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin","volume":"152","author":"Petersen","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13301_bb0245","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/jth.13141","article-title":"Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity","volume":"13","author":"Mahlangu","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13301_bb0250","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/j.1538-7836.2010.03931.x","article-title":"Characterization of canine coagulation factor VII and its complex formation with tissue factor: canine\u2010human cross\u2010species compatibility","volume":"8","author":"Knudsen","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13301_bb0255","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1365-2516.2011.02536.x","article-title":"Pharmacokinetics, Pharmacodynamics, and safety of recombinant canine FVIIa in a pilot study dosing one hemophilia A and one hemostatically normal dog","volume":"17","author":"Knudsen","year":"2011","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13301_bb0260","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1126\/science.3874428","article-title":"Human von Willebrand factor (vWF): Isolation of complementary DNA (cDNA) clones and chromosomal localization","volume":"228","author":"Ginsburg","year":"1985","journal-title":"Science (New York, NY)"},{"key":"10.1111\/jth.13301_bb0265","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1093\/nar\/13.13.4699","article-title":"Construction of cDNA coding for human von Willebrand factor using antibody probes for colony screening and mapping of the chromosomal gene","volume":"13","author":"Verweij","year":"1985","journal-title":"Nucleic Acids Res"},{"key":"10.1111\/jth.13301_bb0270","doi-asserted-by":"crossref","first-page":"19514","DOI":"10.1016\/S0021-9258(19)47144-5","article-title":"Structure of the gene human von Willebrand factor","volume":"264","author":"Mancuso","year":"1989","journal-title":"J Biol Chem"},{"issue":"Suppl. 1","key":"10.1111\/jth.13301_bb0275","first-page":"S32","article-title":"Development of a plasma\u2010 and albumin\u2010free recombinant von Willebrand factor","volume":"29","author":"Turecek","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1111\/jth.13301_bb0280","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1182\/blood.V96.5.1808","article-title":"von Willebrand factor storage and multimerization: 2 independent intracellular processes","volume":"96","author":"Haberichter","year":"2000","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0285","doi-asserted-by":"crossref","first-page":"461238","DOI":"10.1155\/2010\/461238","article-title":"Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies","volume":"2010","author":"Nichols","year":"2010","journal-title":"Thrombosis."},{"key":"10.1111\/jth.13301_bb0290","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ilar.50.2.144","article-title":"Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von Willebrand disease, and factor VII deficiency","volume":"50","author":"Nichols","year":"2009","journal-title":"ILAR J"},{"key":"10.1111\/jth.13301_bb0295","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long\u2010term correction of inhibitor\u2010prone hemophilia B dogs treated with liver\u2010directed AAV2\u2010mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0300","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0305","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ymthe.2006.05.004","article-title":"Evidence of multiyear factor IX expression by AAV\u2010mediated gene transfer to skeletal muscle in an individual with severe hemophilia B","volume":"14","author":"Jiang","year":"2006","journal-title":"Mol Ther"},{"key":"10.1111\/jth.13301_bb0310","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1182\/blood.V88.9.3451.bloodjournal8893451","article-title":"A deletion mutation causes hemophilia B in Lhasa Apso dogs","volume":"88","author":"Mauser","year":"1996","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0315","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.8211118","article-title":"In vivo gene therapy of hemophilia B: sustained partial correction in factor IX\u2010deficient dogs","volume":"262","author":"Kay","year":"1993","journal-title":"Science (New York, NY)"},{"key":"10.1111\/jth.13301_bb0320","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1089\/10430349950017473","article-title":"In vivo evaluation of an adenoviral vector encoding canine factor VIII: high\u2010level, sustained expression in hemophiliac mice","volume":"10","author":"Gallo\u2010Penn","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1111\/jth.13301_bb0325","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood-2002-10-3050","article-title":"Neonatal or hepatocyte growth factor\u2010potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B","volume":"101","author":"Xu","year":"2003","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0330","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1073\/pnas.0409249102","article-title":"Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver\u2010directed neonatal gene therapy","volume":"102","author":"Xu","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.13301_bb0335","first-page":"240a","article-title":"Sustained expression of human factor VIII from peripheral retroviral gene delivery in rabbits and dogs","volume":"90","author":"Greengard","year":"1997","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0340","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2003-01-0167","article-title":"Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion","volume":"102","author":"Powell","year":"2003","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0345","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1073\/pnas.91.6.2353","article-title":"In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs","volume":"91","author":"Kay","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.13301_bb0350","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood.V97.1.107","article-title":"Systemic delivery of an adenoviral vector encoding canine factor VIII results in short\u2010term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs","volume":"97","author":"Gallo\u2010Penn","year":"2001","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0355","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1182\/blood.V88.10.3846.bloodjournal88103846","article-title":"Complete short\u2010term correction of canine hemophilia A by in vivo gene therapy","volume":"88","author":"Connelly","year":"1996","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0360","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1089\/hum.2005.16.811","article-title":"Sustained phenotypic correction of canine hemophilia B after systemic administration of helper\u2010dependent adenoviral vector","volume":"16","author":"Brunetti\u2010Pierri","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1111\/jth.13301_bb0365","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1538-7836.2006.01901.x","article-title":"Helper\u2010dependent adenoviral gene therapy mediates long\u2010term correction of the clotting defect in the canine hemophilia A model","volume":"4","author":"McCormack","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13301_bb0370","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2002-03-0823","article-title":"Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high\u2010capacity adenoviral vectors","volume":"101","author":"Chuah","year":"2003","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0375","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2003-05-1426","article-title":"Helper\u2010dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A","volume":"103","author":"Brown","year":"2004","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0380","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long\u2010term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13301_bb0385","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus\u2010associated virus vector\u2010mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13301_bb0390","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J Clin Investig"},{"key":"10.1111\/jth.13301_bb0395","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/4751","article-title":"Correction of hemophilia B in canine and murine models using recombinant adeno\u2010associated viral vectors","volume":"5","author":"Snyder","year":"1999","journal-title":"Nat Med"},{"key":"10.1111\/jth.13301_bb0400","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1006\/mthe.2000.0031","article-title":"Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV\u2010mediated gene therapy in liver","volume":"1","author":"Wang","year":"2000","journal-title":"Mol Ther"},{"key":"10.1111\/jth.13301_bb0405","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","article-title":"Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver\u2010directed gene therapy","volume":"99","author":"Mount","year":"2002","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0410","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1182\/blood-2004-10-3867","article-title":"Sustained correction of disease in naive and AAV2\u2010pretreated hemophilia B dogs: AAV2\/8\u2010mediated, liver\u2010directed gene therapy","volume":"105","author":"Wang","year":"2005","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0415","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long\u2010term safety and efficacy following systemic administration of a self\u2010complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol Ther"},{"key":"10.1111\/jth.13301_bb0420","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.mt.6300355","article-title":"Optimization of self\u2010complementary AAV vectors for liver\u2010directed expression results in sustained correction of hemophilia B at low vector dose","volume":"16","author":"Wu","year":"2008","journal-title":"Mol Ther"},{"key":"10.1111\/jth.13301_bb0425","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2003-01-0292","article-title":"Sustained phenotypic correction of canine hemophilia A using an adeno\u2010associated viral vector","volume":"102","author":"Scallan","year":"2003","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0430","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/hum.2006.17.427","article-title":"Long\u2010Term Efficacy of Adeno\u2010associated Virus Serotypes 8 and 9 in Hemophilia A Dogs and Mice","volume":"17","author":"Sarkar","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1111\/jth.13301_bb0435","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2010.240","article-title":"Efficacy and safety of long\u2010term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors","volume":"19","author":"Sabatino","year":"2011","journal-title":"Mol Ther"},{"key":"10.1111\/jth.13301_bb0440","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/mt.2010.170","article-title":"Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application","volume":"18","author":"Monahan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1111\/jth.13301_bb0445","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV\u2010Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1111\/jth.13301_bb0450","doi-asserted-by":"crossref","first-page":"277ra28","DOI":"10.1126\/scitranslmed.aaa1405","article-title":"Liver\u2010directed lentiviral gene therapy in a dog model of hemophilia B","volume":"7","author":"Cantore","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1111\/jth.13301_bb0455","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/mthe.2000.0116","article-title":"VSV\u2010G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum","volume":"2","author":"DePolo","year":"2000","journal-title":"Mol Ther"},{"key":"10.1111\/jth.13301_bb0460","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2013-12-545780","article-title":"Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response","volume":"123","author":"Ozelo","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0465","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood.V118.21.2252.2252","article-title":"A Novel FVIIa variant with increased potency and duration of effect compared to Wildtype FVIIa. A study in a dog model of hemophilia A","volume":"118","author":"Pittman","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0470","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood-2008-07-168377","article-title":"Successful treatment of canine hemophilia by continuous expression of canine FVIIa","volume":"113","author":"Margaritis","year":"2009","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0475","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1038\/ncomms3773","article-title":"Platelet\u2010targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A","volume":"4","author":"Du","year":"2013","journal-title":"Nat Commun"},{"key":"10.1111\/jth.13301_bb0480","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/j.1538-7836.2012.04791.x","article-title":"Lentivirus\u2010mediated platelet gene therapy of murine hemophilia A with pre\u2010existing anti\u2010factor VIII immunity","volume":"10","author":"Kuether","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13301_bb0485","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1053\/j.seminhematol.2005.11.009","article-title":"Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents","volume":"43","author":"Poon","year":"2006","journal-title":"Semin Hematol"},{"key":"10.1111\/jth.13301_bb0490","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood-2015-09-671420","article-title":"Sustained correction of FVII deficiency in dogs using AAV\u2010mediated expression of zymogen FVII","volume":"127","author":"Marcos\u2010Contreras","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0495","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2011-09-377630","article-title":"AAV\u2010mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage","volume":"119","author":"Binny","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0500","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.13301_bb0505","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood.V72.2.593.593","article-title":"Cloning of glycoprotein IIIa cDNA from human erythroleukemia cells and localization of the gene to chromosome 17","volume":"72","author":"Rosa","year":"1988","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13301","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622035139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622035139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13301\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:14:27Z","timestamp":1761534867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622035139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1538783622035139"],"URL":"https:\/\/doi.org\/10.1111\/jth.13301","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}